Jounce Therapeutics Stock Forecast, Price & News

-0.62 (-6.39 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $9.09
50-Day Range
MA: $11.06
52-Week Range
Now: $9.09
Volume389,723 shs
Average Volume532,704 shs
Market Capitalization$412.63 million
P/E RatioN/A
Dividend YieldN/A
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:JNCE
Year FoundedN/A



Sales & Book Value

Annual Sales$147.87 million
Cash Flow$2.21 per share
Book Value$5.25 per share


Net Income$56.82 million


Market Cap$412.63 million
Next Earnings Date5/5/2021 (Estimated)


Jounce Therapeutics Presents Preclinical Data...
April 11, 2021 |
Jounce Therapeutics (NASDAQ:JNCE) Stock Price Down 8.7%
March 24, 2021 |
Notable Thursday Option Activity: DG, JNCE, AMC
February 25, 2021 |
JNCE Feb 2021 15.000 put
January 28, 2021 |
JNCE Feb 2021 10.000 put
January 26, 2021 |
JNCE Feb 2021 15.000 call
January 26, 2021 |
JNCE Feb 2021 10.000 call
January 26, 2021 |
See More Headlines


Overall MarketRank

1.65 out of 5 stars

Medical Sector

336th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

41st out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.62 (-6.39 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

Is Jounce Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jounce Therapeutics stock.
View analyst ratings for Jounce Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Jounce Therapeutics?

Wall Street analysts have given Jounce Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,090,000 shares, an increase of 76.2% from the February 28th total of 618,500 shares. Based on an average daily volume of 557,900 shares, the short-interest ratio is presently 2.0 days. Currently, 4.0% of the shares of the company are sold short.
View Jounce Therapeutics' Short Interest

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Jounce Therapeutics

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings data on Thursday, February, 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.50.
View Jounce Therapeutics' earnings history

How has Jounce Therapeutics' stock price been impacted by COVID-19?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JNCE shares have increased by 112.4% and is now trading at $9.09.
View which stocks have been most impacted by COVID-19

What price target have analysts set for JNCE?

6 Wall Street analysts have issued 12-month target prices for Jounce Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Jounce Therapeutics' share price to reach $15.50 in the next year. This suggests a possible upside of 70.5% from the stock's current price.
View analysts' price targets for Jounce Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 62, Pay $845.1k)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 56, Pay $561.11k)
  • Dr. Elizabeth G. Trehu, Chief Medical Officer (Age 61, Pay $555.66k)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder
  • Dr. Robert D. Schreiber, Founder
  • Dr. Drew Mark Pardoll M.D., Ph.D., Founder
  • Dr. Padmanee Sharma, Founder
  • Dr. Louis M. Weiner, Founder (Age 69)
  • Ms. Kimberlee Cobleigh Drapkin CPA, CPA, CFO & Treasurer (Age 53)

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Richard Murray Ph.D has an approval rating of 97% among Jounce Therapeutics' employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $9.09.

How much money does Jounce Therapeutics make?

Jounce Therapeutics has a market capitalization of $412.63 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis.

How many employees does Jounce Therapeutics have?

Jounce Therapeutics employs 128 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is

Where are Jounce Therapeutics' headquarters?

Jounce Therapeutics is headquartered at 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.